on TuHURA Biosciences, Inc.
TuHURA Biosciences (Nasdaq: HURA) Presents at Maxim Healthcare Virtual Summit
On October 23, 2024, TuHURA Biosciences, Inc., an immune-oncology company listed on Nasdaq as HURA, announced their participation in the 2024 Maxim Healthcare Virtual Summit. The event, hosted by Maxim Group LLC, featured Dr. James Bianco, TuHURA's President and CEO, who took part in the Precision and Immune Oncology panel discussion.
TuHURA is in the Phase 3 registration stage, focusing on novel technologies to overcome resistance to cancer immunotherapy. Their leading candidate, IFx-2.0, targets primary resistance to checkpoint inhibitors. A Phase 3 trial of IFx-2.0, alongside Keytruda® for Merkel Cell Carcinoma, is in preparation.
The company is also advancing its Delta receptor technology to develop bi-specific ADCs and PDCs aimed at suppressing immune inhibitory effects in the tumor microenvironment.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TuHURA Biosciences, Inc. news